Aptinyx dementia drug study has poor outcome

EVANSTON - Aptinyx Inc. said its Phase 2 clinical study of a cognitive impairment drug called NYX-458 has ended without success.

The results overall do not support further advancement of the development program by Aptinyx, the biopharmaceutical company said. The company intends to undertake cost-cutting measures to preserve capital and support the exploration of strategic alternatives.

Aptinyx develops transformative therapies for the treatment of brain and nervous system disorders.

Its NYX-458 study in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies did not demonstrate clinically meaningful improvements over placebo on the study's efficacy endpoints, Aptinyx said.

The company said it will also terminate its ongoing Phase 2b study of NYX-783 for use in patients with post-traumatic stress disorder.

"We are very disappointed that the results of this Phase 2 study did not validate the therapeutic potential observed previously in preclinical studies of NYX-458 in models of cognitive impairment," said Dr. Andy Kidd, president and chief executive officer of Aptinyx. "We appreciate the dedication and contributions of patients, investigators and the extensive team that worked on the study."